Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright GlobalĀ Investment Conference Sep 8, 2020
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Jun 30, 2020
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Jun 29, 2020
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Jun 3, 2020